The QualityStocks Daily Thursday, December 22nd, 2022

Today's Top 3 Investment Newsletters

FreeRealTime(ISO) $1.4000 +102.87%

QualityStocks(APCX) $2.7600 +66.27%

MarketClub Analysis(ORIC) $4.7900 +59.67%

The QualityStocks Daily Stock List

IsoPlexis Corp. (ISO)

QualityStocks and MarketBeat reported earlier on IsoPlexis Corp. (ISO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

IsoPlexis Corp. (NASDAQ: ISO) is a life sciences firm that is engaged in the provision of solutions to help develop personalized therapeutics and curative medicines.

The firm has its headquarters in Branford, Connecticut and was incorporated in March 2013 by Kara K. Brower, Rong Fan and Sean Mackay. It operates as part of the medical devices industry, under the healthcare sector. The firm serves consumers in Japan, Korea, Australia, Singapore, Taiwan and China, Switzerland, Israel, Italy, Sweden, Germany, Spain, the Czech Republic, France, Belgium, the United Kingdom, Canada and the United States.

The company is focused on using its systems to advance human health through superhuman cell biology, which is already changing the course of complex illnesses that have plagued humanity and advanced medicines. It operates through its IsoPlexis UK Ltd. subsidiary.

The enterprise provides a cell proteomics platform, including software, chip consumables and instruments that offer a solution to look at protein function at the cellular level. It also offers software which automates analysis with a user interface, dubbed the IsoSpeak software. This software also provides post-warranty services as well as research and support services. The enterprise also provides CodePlex chips which offer multiplexed solutions for ultra-low volume bulk samples. This is in addition to offering IsoCode chips which provide chip solutions for single cell functional proteomics. Furthermore, it provides IsoSpark and IsoLight instruments.

The company recently released its latest financial results which show increases in its revenues. It remains focused on extending its consumer reach around the globe, which will strengthen its relationships with customers and help bring in more investors.

IsoPlexis Corp. (ISO), closed Wednesday's trading session at $1.4, up 102.8691%, on 48,866,157 volume. The average volume for the last 3 months is 5.862M and the stock's 52-week low/high is $0.6017/$10.13.

AppTech Payments (APCX)

Hot Shot Stocks, OTCPicks, HotStockCafe, QualityStocks, Penny Stock Chaser, Stock Traders Chat, FeedBlitz, PennyTrader Publisher, Wise Alerts, StockStreetWire, StockEgg, Penny Invest, CoolPennyStocks, Fierce Analyst, HotOTC, OTCReporter, Penny Stock Rumble, BullRally, Small Cap Firm, StockWireNews, Stock Source, Virmmac Team, Stock Rich, Greenbackers, TopPennyStockMovers, The Penny Stock Alert, Innovative Marketing, The Cervelle Group, MicrocapVoice, The Stock Dork, PennyTrader, SeriousTraders, Real Pennies and TheStockWizards.net reported earlier on AppTech Payments (APCX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

AppTech Payments Corp (NASDAQ: APCX) is a financial technology firm that is engaged in the provision of merchant services and electronic payment processing technologies.

The firm has its headquarters in Carlsbad, California and was incorporated in 1998, on July 2nd. Prior to its name change in December 2021, the firm was known as AppTech Corp. The firm serves consumers across the globe, with a primary focus on the U.S.

The company uses its modular fintech platform to launch digital banking solutions and omni-channel payments which enable commerce experiences that boost business growth. Its proprietary and patented software offers adaptable and progressive products which are available through various synergistic offerings directly to business enterprises, banking institutions and merchants.

The enterprise specializes in e-commerce, gift and loyalty cards, automated clearing house processing and credit card processing. Its merchant services provide financial processing for businesses to accept cashless payments, including wireless payments. Its merchant services software provides integrated solutions like issuing banking authorization, payment tokenization, data encryption and merchant-specific mobile applications for frictionless mobile and digital payment acceptance. The enterprise also develops a 2-way text chat platform which allows secure SMS services, including authentication, reporting, information queries, marketing, notifications and mobile payments.

The company recently appointed new members to its senior technical leadership team and they will be responsible for setting the technical direction and strategy of its fintech platform, while ensuring it is secure, scalable and robust. This will help meet consumer needs more effectively, which will be good for the company’s growth.

AppTech Payments (APCX), closed Wednesday's trading session at $2.76, up 66.2651%, on 5,970,687 volume. The average volume for the last 3 months is 88.383M and the stock's 52-week low/high is $0.4044/$15.20.

ProQR Therapeutics (PRQR)

StockMarketWatch, MarketClub Analysis, MarketBeat, QualityStocks, The Street, StreetInsider, BUYINS.NET, Zacks, Stock Beast, Schaeffer's, InvestorPlace, FreeRealTime and Barchart reported earlier on ProQR Therapeutics (PRQR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

ProQR Therapeutics N.V. (NASDAQ: PRQR) (FRA: 0PQ) (BMV: PRQRN) is a biopharmaceutical firm that is focused on discovering and developing RNA-based therapeutics to help treat genetic disorders.

The firm has its headquarters in Leiden, the Netherlands and was incorporated in 2012, on February 21st by Dinko Valerio, Henri Termeer, Gerard Platenburg and Daniel de Boer. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm has thirteen companies in its corporate family and serves consumers around the globe.

The company primarily focuses on ailments which have limited treatment options, including several forms of inherited blindness like Leber’s congenital amaurosis, autosomal dominant retinitis pigmentosa and Usher syndrome. It is party to license agreements with Leiden University Medical Center, Ionis Pharmaceuticals Inc., Inserm Transfert SA, the Radboud University Medical Center and ProQR Therapeutics VIII B.V., which entail discovering, developing and commercializing potential new medicines for genetic disorders in the nervous system and liver.

The enterprise’s product pipeline is comprised of QR-504a, which is undergoing a phase I clinical trial evaluating its effectiveness in treating fuchs endothelial corneal dystrophy; and QR-1123, which in a phase I/11 trial testing its efficacy in treating autosomal dominant retinitis pigmentosa. It also develops QR-421a, which in a phase I/II trial for the treatment of non-syndromic retinitis pigmentosa and Usher syndrome type 2; and Sepofarsen, which is in a phase 2/3 trial evaluating its efficacy in treating Leber’s congenital amaurosis 10 disease.

The company is focused on advancing its pipeline of therapies for genetic eye illnesses, with the objective of addressing the unmet needs of patients with these indications. The success and approval of its formulations will, in addition to helping patients, also bring in more investors into the company, which will be good for its growth.

ProQR Therapeutics (PRQR), closed Wednesday's trading session at $2.7, up 63.6364%, on 88,681,894 volume. The average volume for the last 3 months is 6,801 and the stock's 52-week low/high is $0.53/$8.60.

Dundee Precious Metals (DPMLF)

QualityStocks and TradersPro reported earlier on Dundee Precious Metals (DPMLF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Dundee Precious Metals Inc. (OTC: DPMLF) (TSE: DPM) (FRA: DPU) is a gold mining firm that is focused on acquiring mineral properties, exploring for, developing, mining and processing precious metals.

The firm has its headquarters in Toronto, Canada and was incorporated in 1983, on September 2nd by Nathan Edward Goodman. It operates as part of the gold industry, under the basic materials sector. The firm serves consumers around the globe.

The company focuses on the development of mineral properties in Armenia, Bulgaria, Canada, and Serbia. It also holds interests in various developing gold, silver, and copper exploration properties located in Canada, Serbia, Bulgaria, and Ecuador. The company operates through the Chelopech and Ada Tepe in Bulgaria; Tsumeb in Namibia; and Corporate and Other reportable segments. The Corporate and Other segment consists of general and administrative costs, corporate social responsibility expenses, exploration and development projects, and other income and cost items.

The enterprise has expertise in acquisition, exploration, and processing of gold, silver, and other minerals. Its principal operating assets include the Chelopech operation, which produces a gold-copper concentrate containing gold, silver, copper and a pyrite concentrate containing gold located to the east of Sofia, Bulgaria; the Ada Tepe operation that produces a gold concentrate containing gold and silver located in southern Bulgaria, near the town of Krumovgrad; and the Tsumeb smelter, a complex copper concentrate processing facility located in Namibia.

The firm recently announced its latest operating and financial results, with its CEO noting that they remained focused on maintaining financial strength while creating value for their shareholders.

Dundee Precious Metals (DPMLF), closed Wednesday's trading session at $4.93, off by 2.9528%, on 6,801 volume. The average volume for the last 3 months is 1,700 and the stock's 52-week low/high is $3.95/$6.88.

Clone Algo Technologies (CATI)

We reported earlier on Clone Algo Technologies (CATI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Clone Algo Technologies Inc. (OTC: CATI) is a technology firm that is focused on the development of AI-based algorithms and risk management systems.

The firm has its headquarters in Chapel Hill, North Carolina and was incorporated in 2013, on March 7th by Jon Fahlberg. Prior to its name change in September 2014, the firm was known as Travelsafe Inc. It operates as part of the shell companies industry, under the financial services sector. The firm serves consumers in the United States.

The company operates social investment networks. It develops artificial intelligence trading systems for financial markets using a range of algorithms combined with timing technology and risk management systems.

The enterprise’s products include a social investment network application known as Clone Algo, which allows users to clone trades from master accounts to users’ own accounts with connected brokers, banks, and hedge funds using algorithms, and advanced cloning and non-predictive timing technology. It ushers the social trading revolution and helps the users create passive income by cloning algorithms which automatically trade forex, shares, gold, and CFDs to the account holder's brokerage account. It also offers a mobile banking system for do it yourself banking dubbed AlgoTrust; and a hotel booking and management system known as HomeAway, for booking discounted hotel room rates.

The firm, through its wholly owned subsidiary, recently entered into a merger agreement with ECO Integrated Technologies Inc. This move will open it up to new growth and investment opportunities while also creating value for its shareholders.

Clone Algo Technologies (CATI), closed Wednesday's trading session at $1.29, even for the day. The average volume for the last 3 months is 2,967 and the stock's 52-week low/high is $0.40/$5.00.

Aker Carbon Capture (AKCCF)

MarketBeat and InvestorPlace reported earlier on Aker Carbon Capture (AKCCF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Aker Carbon Capture ASA (OTCQX: AKCCF) (FRA: 606) is a holding firm that is focused on providing products, technology and solutions within the field of carbon capture, utilization and storage.

The firm has its headquarters in Lysaker, Norway and was incorporated in 1996. It operates as part of the pollution and treatment controls industry, under the industrials sector. The firm serves consumers across the globe, with a primary focus on consumers in Norway, Denmark and the United Kingdom.

The company’s objective is to capture carbon for a brighter and more sustainable future, using environmentally friendly and unique solutions for removing carbon dioxide emissions. It operates as an Aker Horizons Holding AS subsidiary. The company’s activities are divided into the following segments: Cement production; Gas to power; Bio or waste to energy generation; and Blue hydrogen.

The enterprise’s Advanced Carbon Capture technology can be applied across a range of industries onshore. The carbon capture process uses a mixture of water and organic amine solvents to absorb the CO2 that can be applied on emissions from various sources, including gas, coal, cement, refineries, and waste-to-energy through to hydrogen and other process industries. The enterprise provides carbon capture plants under the Just Catch and Big Catch brands, as well as mobile test units.

The company will be partnering with Viridor, the largest waste firm in the United Kingdom, in a pre-FEED study for the Runcorn CCS project. This move will not only create green jobs while realizing major emission reductions but also generate value for Aker’s shareholders.

Aker Carbon Capture (AKCCF), closed Wednesday's trading session at $1.1979, up 0.511831%, on 2,967 volume. The average volume for the last 3 months is 35 and the stock's 52-week low/high is $1.05/$3.68.

Adbri Ltd (ADBCF)

MarketBeat reported earlier on Adbri Ltd (ADBCF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Adbri Limited (OTC: ADBCF) (FRA: GHO) (ASX: ABC) is a construction material and industrial mineral manufacturing firm that is involved in manufacturing, importing, distributing and marketing construction materials.

The firm has its headquarters in Sydney, Australia and was incorporated in 1882. Prior to its name change in May 2020, the firm was known as Adelaide Brighton Ltd. It operates as part of the building materials industry, under the basic materials sector. The firm primarily serves consumers in Australia.

The company operates through the Cement, Lime, Concrete and Aggregates, and Masonry divisions. The Cement, Lime, Concrete and Aggregates divisions include products under the Cockburn Cement, Adelaide Brighton Cement, Northern Cement, MCI, Swan Cement, Southern Quarries, Hy-Tec, Direct Mix Concrete, Penrice and Peninsula Quarries brands. On the other hand, the Concrete Products division provides blocks, concrete bricks, erosion control products, pavers, retaining walls, architectural masonry and reconstituted stone veneers.

The enterprise offers lime, cement, aggregates, premixed concrete and sand; various concrete bricks, pavers, besser blocks and retaining wall blocks; and industrial minerals, which includes stockfield minerals and fillers for glass manufacturing, agricultural lime products and quick and hydrated lime for industrial processing and water treatment applications. It provides its products to non-residential and residential construction, mining, industrial manufacturing and engineering construction markets.

The company, which recently released its latest financial results showing revenue growth, remains focused on executing against its strategic priorities to deliver business improvement and growth. This will, in turn, help create value for the company’s shareholders.

Adbri Ltd (ADBCF), closed Wednesday's trading session at $1.15, even for the day. The average volume for the last 3 months is 15,000 and the stock's 52-week low/high is $0.90/$2.102934.

Wuling Motors (WLMTF)

We reported earlier on Wuling Motors (WLMTF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Wuling Motors Holdings Limited (OTC: WLMTF) (FRA: 6LY) (HKG: 0305) is an investment holding firm that is focused on manufacturing and trading in engines and parts, specialized vehicles, automotive components and accessories.

The firm has its headquarters in Central, Hong Kong and was incorporated in 1992, on August 24th. Prior to its name change in June 2011, the firm was known as Dragon Hill Wuling Automobile Holdings Ltd. It operates as part of the auto parts industry, under the consumer cyclical sector. The firm serves consumers around the world, with a main focus on consumers in the People’s Republic of China.

The company operates through the Automotive Components and Other Industrial Services, Vehicles’ Power Supply Systems, Commercial Vehicles Assembly, and Others segments. It generates the majority of its revenues from the automotive components and other industrial services segment. Geographically, it derives most of its revenue from Mainland China. The company operates as a Wuling (Hong Kong) Holdings Limited subsidiary.

The enterprise provides engines and automotive components to commercial vehicles and passenger vehicles. It also provides water and power supply, and industrial services; trades in steel; and manufactures specialized vehicles, including energy vehicles. This is in addition to providing petrol and motorcycle engines; and investing in properties and other activities.

The company recently entered into an industrials cooperation agreement with Mushroom Autolink Information Technology Company Limited to jointly develop a new track for intelligent connected vehicles. This move will not only help extend the company’s consumer reach but bring in additional investments, which will positively influence its overall growth.

Wuling Motors (WLMTF), closed Wednesday's trading session at $0.1001, even for the day. The average volume for the last 3 months is 201,204 and the stock's 52-week low/high is $0.07/$0.225.

Compass Pathways PLC (CMPS)

QualityStocks, InvestorPlace, MarketBeat, Daily Trade Alert, StreetInsider, Schaeffer's, Trades Of The Day and The Street reported earlier on Compass Pathways PLC (CMPS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Over the past couple of years, Big Pharma and investors have poured millions of dollars into psychedelic research. Initial studies have found that psychedelic drugs such as psilocybin, mescaline and ketamine may offer significant mental health benefits.

When paired with physiotherapy, these hallucinogenic drugs can deliver profound benefits against conditions such as post-traumatic stress disorder, depression, and eating disorders. Studies have indicated that psychedelics deliver these benefits by causing users to have profound changes in patients’ beliefs about consciousness, meaning and purpose.

A recently published study sought to understand the association between serotonin receptors, mystical-like experiences, mindfulness and psilocybin. Psilocybin is the main psychoactive agent in magic mushrooms, and in some studies, it has exhibited moderate success against mental health disorders, including treatment-resistant depression and OCD.

Researchers found that study participants who reported mystical-type experiences while under the influence of psilocybin were more likely to exhibit mindfulness. Furthermore, these participants also exhibited reduced activity in their serotonin 2A receptors.

Recognizing the benefits psychedelics can have against a variety of mental health disorders, researcher Anna Søndergaard and her team sought to answer a couple of key questions: Would the enhanced mindfulness experienced after taking psychedelics continue over the near and future term? Was there any correlation between taking psilocybin and having a mystical experience? Did serotonin play any role in mystical experiences or the development of mindfulness?

The researchers defined mindfulness as awareness that develops by “paying attention on purpose in the present moment.”

The researchers recruited 39 participants for their the study, screening the participants for pregnancy, medical issues and drug use before providing them with an appropriate dose of psilocybin. The participants were asked to fill out a mystical experience questionnaire six hours after they took psilocybin and reveal whether they felt ecstasy, a sense of unity, lost their sense of time or couldn’t even describe their experience in words. They were also required to take the Mindful Attention and Awareness Scale three months before and after they were dosed with psilocybin.

Analysis of the final data revealed an 8.1% increase in mindfulness after taking psilocybin. Additionally, the researchers found that participants who had more intense mystical experiences exhibited higher scores for mindfulness, with their brain scans revealing diminished binding activities at serotonin receptors in the right side of the amygdala.

Researchers noted that this may indicate that the right side of the amygdala plays a greater role in mindfulness compared to the left side but stated that more research was needed to determine the role serotonin plays in psychedelic treatment.

The world is likely to learn much more about psychedelics given the pace at which various startups such as Compass Pathways PLC (NASDAQ: CMPS) are undertaking clinical studies on a several of these compounds.

Compass Pathways PLC (CMPS), closed Wednesday's trading session at $8.93, off by 1.9759%, on 202,697 volume. The average volume for the last 3 months is 32.019M and the stock's 52-week low/high is $6.54/$24.25.

NIO Inc. (NIO)

Green Car Stocks, InvestorPlace, Schaeffer's, The Street, MarketClub Analysis, MarketBeat, Daily Trade Alert, Trades Of The Day, StocksEarning, Kiplinger Today, The Online Investor, QualityStocks, Zacks, StreetInsider, StockMarketWatch, INO Market Report, BUYINS.NET, Early Bird, Cabot Wealth, Wealth Insider Alert, The Wealth Report, CNBC Breaking News, InvestorsUnderground, Investopedia, Daily Wealth, TradersPro, wyatt research newsletter, Energy and Capital, Investors Alley, CRWEWallStreet, FreeRealTime, Jim Cramer, Wealth Daily, InvestorsObserver Team, AllPennyStocks, MarketClub, TopPennyStockMovers, Top Pros' Top Picks, Stock Market Watch and InvestorIntel reported earlier on NIO Inc. (NIO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

NIO displayed its array of electric vehicles at the December Sweden Auto Show, which focused on green technology and sustainable development in Europe; among the vehicles on display was a supercar concept as well as the typical NIO Electric Vehicle spectrum. This display at the eCarExpo show in Sweden is timed to coincide with the launch of the NIO EV selection in several markets throughout Europe.

At the eCarExpo, the ET5, EL7, and ET7, as well as the EP9 supercar, were among the models on display. The EP9 supercar actually appeared at the event to demonstrate the emphasis NIO Inc. (NYSE: NIO) places on its electric vehicles. When the EP9 was tested in 2016, this supercar broke several records for electric vehicles. It was the fastest electric vehicle to complete a renowned race in a 7:05.12 lap period.

During the show, NIO welcomed brand-new clients to take a test drive in its model ET7 sedan. According to NIO, those who participated in the test drive were quite impressed and generally offered insightful feedback.

This same NIO ET7 model has recently been named the 2022 Car of the Year by Auto Motor & Sport Sverige. This is a significant accomplishment for NIO, as it had only recently launched its vehicle line in Europe. This award is typically given to only high-end electric vehicles on the continent. NIO boasts about its ET7 in China, which has a 150-kilowatt-hour battery and a one thousand kilometer range.

NIO not only launched its EV selection in Europe, but part of that launch also included the introduction of NIO’s battery swap stations. This is the point where NIO electric vehicles are able to interchange a used-up battery with a fully charged one in less than seven minutes. In fact, NIO opened the first battery-swap station site in Sweden last month. Additionally, NIO is establishing centers of experience in Sweden. Early this month, Swedes already saw the first experience center at Westfield Täby Mall Centrum in Stockholm, which had been established by NIO.

This development clearly shows a progressing auto company with multiple strategies concerning EVs for the continent at large. According to the NIO founder William Li, the company plans to introduce a cost-effective model in the upcoming year, along with a number of other new brands for the international markets.

In the upcoming years, NIO also hopes to introduce flawless models to the Australian market. As more electric cars enter that market, motorists will have no choice but to transition.

NIO Inc. (NIO), closed Wednesday's trading session at $11.29, off by 2.7562%, on 32,468,886 volume. The average volume for the last 3 months is 315,922 and the stock's 52-week low/high is $8.375/$33.80.

McEwen Mining Inc. (MUX)

MarketClub Analysis, QualityStocks, Wall Street Resources, InvestorBrandNetwork, Tiny Gems, MiningNewsWire, MissionIR, SeriousTraders, SmallCapRelations, Stocks to Buy Now, Gold Investment Letter, MarketBeat, Schaeffer's, The Street, Super Stock Picker, StockOodles, StreetInsider, Energy and Capital, Hit and Run Candle Sticks, Zacks, Uncommon Wisdom, Pennybuster, BUYINS.NET, Wealth Daily, InvestorPlace, Marketbeat.com, Streetwise Reports, Top Pros' Top Picks, The Best Newsletters, Money and Markets, Money Morning, Market FN, Lebed.biz, AllPennyStocks, Investment House, INO.com Market Report, StreetAuthority Daily, Stock Beast, Stock Gumshoe, Cabot Wealth and StockMarketWatch reported earlier on McEwen Mining Inc. (MUX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

McEwen Mining (NYSE: MUX) (TSX: MUX), a gold and silver producer with operations in Nevada, Canada, Mexico and Argentina, is reporting on its October and November production as well as forecasting numbers for the remainder of the year; the company also released its guidance for 2023. According to the announcement, total production for October and November reached an estimated 26,700 gold equivalent ounces (“GEO”) with preliminary costs per ounce from McEwen’s 100%-owned operations of $826 for cash costs and $1,088 for all-in sustaining. The report noted that at San José Mine, costs per ounce for October and November were $1,361 for cash costs and $1,745 for all-in sustaining. The report also noted that consolidated production guidance for 2023 represents an 11% to 25% increase from 2022 forecast production. The bottom line? Production is increasing and costs per ounce are falling, the company stated. “As we end 2022, we would like to give our shareholders an update on our recent production results and costs, which illustrate the turnaround we are executing as well as our guidance for 2023. We had a difficult start to 2022, but it is clear that we are trending up and in the right direction as we move into the new year,” said McEwen Mining chair and chief owner Rob McEwen in the press release.

To view the full press release, visit https://ibn.fm/Wm5Kx

About McEwen Mining Inc.

McEwen Mining is a gold and silver producer with operations in Nevada, Canada, Mexico and Argentina. In addition, it owns 68% of McEwen Copper, which owns the large, advanced-stage Los Azules copper project in Argentina. The company’s goal is to improve the productivity and life of its assets with the objective of increasing its share price and providing a yield. McEwen’s chair and chief owner has personally provided the company with $220 million and takes an annual salary of $1. To learn more about the company, visit www.McEwenMining.com.

McEwen Mining Inc. (MUX), closed Wednesday's trading session at $5.87, up 3.7102%, on 318,202 volume. The average volume for the last 3 months is 1.092M and the stock's 52-week low/high is $2.81/$10.20.

HIVE Blockchain Technologies (HIVE)

QualityStocks, InvestorPlace, MarketClub Analysis, MarketBeat, StreetInsider, Marketbeat.com, StockMarketWatch, Greenbackers, Hit and Run Candle Sticks, Barchart, Stock Market Watch, WealthMakers, StockOodles, StreetAuthority Daily, The Online Investor, TopStockAnalysts, Wall Street Resources and smartOTC reported earlier on HIVE Blockchain Technologies (HIVE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

HIVE Blockchain Technologies (NASDAQ: HIVE) (TSX.V: HIVE) (FSE: HBF) today announced that all resolutions considered at its 2022 annual meeting of shareholders on Dec. 20, 2022, were approved by its shareholders. The company also provided a corporate update for its fiscal third quarter ending Dec. 31, 2022. Among the resolutions, shareholders present in person or represented by proxy at the meeting approved/re-approved all director nominees, which were duly elected or re-elected to HIVE’s board of directors, as well as the company’s stock option plan. In addition, the company announced acquisitions of Bitmain Antminer S19j Pro ASIC miners at opportunistic prices, with the move intended to take HIVE to target three exahash in the New Year.

To view the full press release, visit https://ibn.fm/PNGni

About HIVE Blockchain Technologies Ltd.

HIVE Blockchain Technologies went public in 2017 as the first cryptocurrency mining company with a green energy and ESG strategy. HIVE is a growth-oriented technology stock in the emergent blockchain industry. As a company whose shares trade on a major stock exchange, it is building a bridge between the digital currency and blockchain sector and traditional capital markets. HIVE owns state-of-the-art, green energy-powered data centre facilities in Canada, Sweden and Iceland, where it endeavours to source only green energy to mine digital assets such as bitcoin on the cloud. Since the beginning of 2021, HIVE has held in secure storage the majority of its treasury of ETH and BTC derived from mining rewards. The company’s shares provide investors with exposure to the operating margins of digital currency mining, as well as a portfolio of cryptocurrencies, primarily BTC. Because HIVE also owns hard assets such as data centers and advanced multi-use servers, it believe its shares offer investors an attractive way to gain exposure to the cryptocurrency space. For more information and to register to HIVE’s mailing list, please visit www.HIVEBlockchain.com.

HIVE Blockchain Technologies (HIVE), closed Wednesday's trading session at $1.61, off by 6.9364%, on 1,093,191 volume. The average volume for the last 3 months is 166.15M and the stock's 52-week low/high is $1.57/$15.8.

The QualityStocks Company Corner

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has announcedthat its I-GO(TM) Commercial Urban Delivery EV has arrived inEurope; specifically, sample vehicles are on their way toIreland-based Newgate Motor Group, with an expected delivery forearly next month. Initially, delivery was scheduled for December,but COVID-related shutdown issues caused the delay. According tothe announcement, Mullen’s I-GO is an urban commercial deliveryvehicle designed to meet the growing demand for quick deliveries indense cities throughout Europe that have space constraints; theI-GO is EU standard homologated, certified, and ready for sale ininitial markets of the United Kingdom, Germany, Spain, France andIreland. Last month Mullen entered into an agreement to havethe Newgate Motor Group become the marketing, sales, distributionand servicing agent for the I-GO in Ireland and the United Kingdom.With more than 40 years of experience in the motor industry,Newgate is well respected in the auto industry and representsseveral brands including Renault/Dacia, Kia and Mercedes-Benz.Newgate also has substantial relationships in the vehicledistribution business throughout the United Kingdom and variousparts of Europe. “The initial I-GO samples have arrived in Europeand are now on their way to Newgate in Ireland,” said MullenAutomotive CEO and chairman David Michery in the press release. “Weare excited for sales and service to get up and running withNewgate. Once established, we will look further into otheropportunities for the European market. The I-GO is a greatalternative vehicle for delivery in dense metro European cities.The small size is perfect for maneuverability on tight Eurostreets, and the zero emissions and lower cost of ownership is agreat combination for our potential commercial customers.”

To view the full press release, visit https://ibn.fm/ZKWm2

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Wednesday's trading session at $0.2289, up 2.6918%, on 169,803,090 volume. The average volume for the last 3 months is 346,453 and the stock's 52-week low/high is $0.18/$6.05.

Recent News

Knightscope, Inc. (NASDAQ: KSCP)

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc. (NASDAQ: KSCP).

Knightscope, Inc. (NASDAQ: KSCP) , a leading developer of autonomous security robots, todayannounces that it has been featured in a broadcast viaNetworkNewsAudio (“NNA”), a solution that delivers additionalvisibility, recognition and brand awareness in the investmentcommunity via distribution to thousands of syndication points. Theaudio news release covers Knightscope’s recent securement of thelargest single contract in the company’s history alongside two newcontracts from cities in New York and Georgia.

To hear the audio production, visit: https://www.nnw.fm/FjVcX

To read the original press release, visit: https://nnw.fm/A9OK4

Knightscope, Inc. (NASDAQ: KSCP), founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities targeting to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics, artificial intelligence and electric vehicles.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including multiple Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country.

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire. You can learn more about the crime fighting wins at www.knightscope.com/crime

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology (Made in the USA)
  • Operating for more than 1 million hours in the field and securing contracts across five time zones, from Hawaii to Rhode Island
  • Raising over $100 million since inception to build its technology from scratch and generating over $13 million in lifetime revenue, validating both the market opportunity and the technology

Growth Capital & Proposed Nasdaq Listing

With backing from more than 28,000 investors and four major corporations and over $100 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

On December 1, 2021, Knightscope announced the commencement of an offering of up to $40 million of its Class A common stock, with shares to be listed immediately following closing on the Nasdaq Global Market under the ticker symbol ‘KSCP’. The offering is for up to 4 million shares priced at $10 per share. Learn more at www.knightscope.com/investors

Company Mission – Reimagining Public Safety

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting the 2+ million law enforcement and security professionals across the country.

Crime has an estimated negative economic impact in excess of $2 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one-to-one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings – and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $3 to $9 per hour, compared with approximately $85 for an armed off-duty law enforcement officer and $15 to $35 for an unarmed security guard.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has nine patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’. Learn more at www.knightscope.com/ksoc

The ASRs and the related technologies were developed ground up by the company and are Made in the USA.

The Robot Roadshow

Knightscope has created the ultimate hybrid physical and virtual event, bringing its Autonomous Security Robot technologies to cities across the country for interactive and in-person demonstrations.

Each roadshow landing is hosted virtually by a Knightscope expert, and visitors can interact directly with each of the company’s ASRs and see the Knightscope Security Operations Center (KSOC) user interface in action. Learn more at www.knightscope.com/roadshow

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.

Chief Financial Officer Mallorie Burke is a seasoned financial executive and strategic advisor for both private and publicly traded technology companies with a successful track record of mergers & acquisitions, corporate growth and exit strategies, including public listings.

General Counsel Peter Weinberg leverages 30 years of diverse corporate counsel experience, spanning from startups to well-established companies, private and public. He has significant experience training personnel at all levels in critical areas to improve corporate compliance and productivity.

Knightscope, Inc. (NASDAQ: KSCP), closed Wednesday's trading session at $1.66, up 1.2195%, on 346,453 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $6.05/$.

Recent News

REZYFi, Inc.

The QualityStocks Daily Newsletter would like to spotlight REZYFi, Inc.

  • REZYFi is targeting licensed and permitted cannabis companies,owners of real estate who lease to cannabis companies, andcompanies and individual homeowners who seek a variety of realestate-related first and additional mortgage-based financingand project-specific financing
  • The sale of legal recreational marijuana in California in 2016reached $2.69 billion and is expected to grow to $6.59 billionby 2025. Since passing laws for recreational marijuana,California saw a 50% increase in the legal marijuana marketfrom 2017 to 2018
  • REZYFi is licensed in 36 states and plans to expand to allstates in the future

Throughout most of 2022, mortgage rates were rising due to theFederal Reserve’s increased interest rates to counter soaringinflation. However, mortgage rates have started dropping in recentweeks, reporting a downward trend for the fifth consecutive week.According to Freddie Mac, the 30-year fixed-rate mortgage averaged6.31% in the week ending December 15, down from 6.33% during theweek prior. According to the Mortgage Bankers Association, therehas been an uptick in mortgage applications, with more peoplelooking to take advantage of the trend in lower rates (https://ibn.fm/CXJOi).

REZYFi is a real estate-oriented mortgage company servicing the needs ofboth traditional and non-traditional consumers and businesses. Thecompany’s target markets include licensed and permitted cannabiscompanies, owners of real estate who lease to cannabis companies,and companies and individual homeowners who seek a variety of realestate-related first and additional mortgage-based financing andproject-specific financing, like solar installations or real estatedevelopment projects.

REZYFi, Inc. is a cannabis mortgage bank servicing the needs of both traditional and non-traditional consumers and businesses. Its target markets include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing and project-specific financings, such as solar installations and real estate development projects.

Headquartered in Miami, Florida, REZYFi operates through two wholly owned subsidiaries – REZYFi Lending, which primarily addresses emerging real estate-related financing opportunities, and ResMac Inc., the company’s traditional mortgage origination, correspondent and servicing operation. REZYFi is currently licensed in 34 U.S. states, with plans to expand to all remaining states later this year.

REZYFi is positioned as one of first cannabis mortgage bankers in the U.S., while most traditional lenders are still reticent to serve the state-licensed cannabis industry.

Operations

REZYFi Lending

REZYFi Lending leverages a wide network to offer options such as 15- and 30-year fixed-rate loans, FHA loans, VA loans, reverse mortgages, jumbo loans and adjustable-rate mortgages.

Looking ahead, the company expects increased funding in marketing and loan agents to drive significant origination growth over the next two years, further supported by the planned launch of a high-margin cannabis division later this year.

ResMac Inc.

ResMac has been in operation for 13 years, having closed more than 20,000 loans for more than 15,000 clients. The company expects to accumulate $285 million in retail origination in 2023, alongside $250 million in wholesale origination for the same period. ResMac is further targeting $600 million in origination through its mortgage correspondent operations for 2023.

Through its ResMac subsidiary, REZYFi operates as a direct lender and originator of residential mortgages, with active mortgage correspondent and mortgage servicing operations. Through its correspondent segment, ResMac primarily purchases and aggregates residential mortgages from trusted third-party originators.

The company intends to harvest the database of customers within its mortgage servicing operations as an essential source of additional growth, especially relative to the new alternative residential loan programs being offered.

Corporate Strengths

  • Experience – REZYFi is led by a seasoned management team with significant expertise spanning a wide range of real estate and financing subsectors. The team also has extensive experience in the cannabis and hemp marketplace, which the company intends to leverage as it navigates the changing landscape of the cannabis industry while sourcing the best opportunities in the sector.
  • Network of Independent Brokers – Over the past five years, REZYFi has developed an extensive network of independent mortgage-related brokers and licensed loan officers. The company is currently training the network members on its new service offerings, with many already launching sales efforts. REZYFi believes this network will be a vital asset moving forward as other firms in the sector terminate relationships in the face of slowing mortgage business in a rising interest rate environment.
  • Proprietary Technology – REZYFi has invested heavily in designing, building and implementing proprietary automated/machine learning technology to shorten loan processing timeframes and increase efficiencies, allowing it to operate its legacy business at staffing levels meaningfully below those of its competitors.

Market Overview

REZYFi’s diversified approach to the real estate lending sector positions it to capitalize on growth in multiple verticals in the years to come.

In the first quarter of 2022, lenders issued 2.71 million residential loans, with the average balance for a first mortgage climbing to a record high of $298,324 in 2021, according to the Mortgage Bankers Association. This trend is expected to continue, with Freddie Mac forecasting a 10.4 percent increase in home prices in 2022 and a 5.0 percent bump in 2023. Growth prospects in the cannabis industry paint a similar picture.

The National Association of Realtors® issued a report in April 2021 examining the correlation between cannabis legalization and real estate demand. In states where prescription and recreational cannabis use is legal, more than a third of surveyed agents reported an increase in demand for warehouses. Likewise, 23 percent of those surveyed reported an increase in demand for storefronts, and 28 percent observed increased demand for land. As other states look to join the 19 that have embraced full cannabis legalization, this rising demand could create an opportunity for REZYFi’s cannabis-focused initiatives.

In total, an analysis by market research firm Business Research Insights projects the global loan servicing market to reach a value of nearly $1.5 billion by 2028, up from $680.8 million in 2021. Those figures represent a CAGR of 11.0 percent during the forecast period of 2022-2028.

Management Team

John Vu, Esq., is CEO of REZYFi, Inc. He has more than two decades of experience in the mortgage and commercial banking industry. He has filled many senior and executive management positions in high-producing mortgage banks, including C-level assignments. He has also served as general counsel for a nationally associated commercial bank. Mr. Vu brings considerable cannabis industry expertise to REZYFi. He has served as a corporate attorney to multiple cannabis cultivators, manufacturers and retailers.

Ji Ji Zhang, Esq., is CFO of REZYFi, Inc. He is a multifaceted entrepreneur who owns a law firm, a portfolio of hotels and a high-producing mortgage bank. Mr. Zhang is also an investor in the development of a cannabis business park. He brings more than five years of experience in mortgage banking to REZYFi, having developed Freddie Mac and HUD licenses and amassed a managed portfolio valued at over $300 million.

Kevin Heckemeyer is President of REZYFi, Inc. He has more than 25 years of experience in mortgage banking. He has built and sold several high producing mortgage businesses. In his current roles with ResMac, he is responsible for production and operations.

Spencer Dang is Chief Credit Officer of REZYFi, Inc. He has more than a decade of experience in mortgage operations. He is a direct endorsement underwriter for HUD and has specialized in non-QM underwriting. Under his watch as an underwriter, he has never had a single repurchase.


Recent News

chart

QSAM Biosciences Inc. (OTCQB: QSAM)

The QualityStocks Daily Newsletter would like to spotlight QSAM Biosciences Inc. (OTCQB: QSAM).

Prostate cancer is the most common cancer in American men,affecting an estimated 3.2 million men in the country. While we don’t know exactly what causes prostatecancer, risk factors for the disease include age, family history, diet, obesity and ethnicity.

Research has indicated that there may be some association between obesity and diet and the prevalence of prostate cancer.These past studies suggest that regular exercise and a balanceddiet may help to reduce the risk of prostate cancer.

Urologist Dr. Stephen Freedland, director of Cedars-Sinai MedicalCenter’s Center for Integrated Research in Cancer and Lifestylerecently conducted a study to determine if diet could have aneffect on prostate cancer risk. More specifically, Freedland andhis colleagues were interested in finding out if eating aplant-only diet had any effect on one’s risk of developing prostate cancer. The researchers analyzed the results of a comprehensive review ofthe body of literature on prostate cancer risk and plant-baseddiets.

As studies are undertaken to understand how different cancers startand grow, effort is also being directed by entities such as QSAM Biosciences Inc. (OTCQB: QSAM) to develop better treatments for people who are already afflictedwith these conditions.

QSAM Biosciences Inc. (OTCQB: QSAM) is a clinical stage biotechnology company focused on bringing to market targeted therapeutic radiopharmaceuticals. The company is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients.

QSAM Biosciences was founded in 2020 by Executive Chairman Dr. C. Richard Piazza and CEO Douglas Baum. It is headquartered in Austin, Texas.

CycloSam®

CycloSam®, QSAM Biosciences’ initial technology, is a clinical-stage bone targeting radiopharmaceutical invented by world-renowned scientists at IsoTherapeutics Group LLC. By leveraging a patented, low specific activity form of Samarium-153 (resulting in far less undesirable europium impurity) and what management believes to be a superior chelating agent in DOTMP, CycloSam is designed to selectively target sites of high bone mineral turnover to deliver a prescribed tumor-killing dose of radiation to the bone tumor sites while minimizing radiation exposure to nearby healthy tissue. These parameters are currently being tested in an FDA-cleared clinical trial.

CycloSam® has been shown in laboratory testing to cause significantly less (30x less) buildup of long-lived radionuclidic impurities than prior FDA-approved drugs, which management believes will enable the ability to safely administer therapeutic doses via higher and multiple-dose regimens and effectively expand its potential clinical utility to therapeutic uses in areas of high unmet medical needs.

The indications for CycloSam® currently being evaluated by QSAM Biosciences include:

  • Metastatic Bone Cancers – On April 28, 2022, QSAM Biosciences announced that the first patient had commenced treatment in its clinical trial evaluating CycloSam in patients with metastatic bone cancer. As noted in the release, the study is a Phase 1 open-label, dose-escalation trial to evaluate the safety, tolerability, dosimetry, and preliminary efficacy of CycloSam®.
  • Pediatric Osteosarcoma/Ewing’s Sarcoma – On February 2, 2022, the company announced that the U.S. FDA has granted Rare Pediatric Disease Designation to CycloSam for the treatment of osteosarcoma. Combined with a previously granted orphan drug designation for osteosarcoma received in 2021, this milestone “may allow QSAM to potentially bring CycloSam® to market more rapidly through additional incentives and eligibilities,” according to CEO Douglas Baum.
  • Bone Marrow Ablation – In a 2020 single patient Investigational New Drug (IND) study, an investigator concluded that high-dose CycloSam® can be administered safely to ablate bone marrow in advance of a stem cell transplant with no apparent renal toxicity and no unexpected adverse events attributable to the drug.

QSAM Biosciences’ preclinical and clinical development pipeline is supported by a strong IP portfolio. The company has secured 14 patents across three distinct patent families spanning the U.S., Japan, Canada and the European Union.

Market Outlook

Through its ongoing development of CycloSam®, QSAM Biosciences is targeting multiple large and underserved market opportunities. According to the American Cancer Society, roughly 400,000 new cases of malignant bone metastasis are diagnosed annually in the U.S. alone. Additionally, QSAM will pursue indications for osteosarcoma and Ewing’s sarcoma that are the most common primary malignancies of bone tissues in children.

Despite this pressing need, the current standard of care for bone cancer is aggressive and suboptimal, leading to marginal success with significant side effects and poor long-term survival prognosis. As a result, QSAM Biosciences estimates a sizable market opportunity for its development pipeline.

  • Bone Metastasis has an estimated total addressable market of $20 billion in the U.S. based on total new cases and comparable drug pricing.
  • Osteosarcoma/Ewing’s Sarcoma have a total addressable market of roughly $125 million in the U.S. based on approximately 1,000 new cases in 2021.
  • The total addressable market for Bone Marrow Ablation is projected at $1 billion, with an estimated 32,000 procedures completed annually.

The company anticipates that the ability to administer CycloSam® for higher and multiple-dose regimens may expand its clinical utility for therapeutic uses in additional areas of high unmet medical needs.

Management Team

QSAM Biosciences is led by an experienced management team and board with an extensive record of FDA approvals, big pharma partnerships and M&A transactions.

Dr. C. Richard Piazza is the Executive Chairman of QSAM Biosciences. Since 2017, he has also served as President and CEO of IGL Pharma Inc., the licensor of CycloSam®, and as a consultant to IsoTherapeutics Group LLC, the inventors of the technology. Dr. Piazza also currently serves on the board of directors of NovaScan LLC, a privately held cancer detection and diagnostics company. He has more than 48 years of health care experience in both medical devices and pharmaceutical/biotech and has led several technology companies to market success, including numerous FDA approvals in both sectors. Dr. Piazza obtained a BS in Economics and a BS in Speech Pathology from the State University of New York and an MA & PhD in Economics from the University of Buffalo and Leeds University.

Douglas R. Baum is the company’s CEO and Director. He brings to QSAM Biosciences over 30 years of experience in the bioscience and biotech industries, including development, FDA/EMA approval and commercialization of multiple drugs and medical devices. Mr. Baum has overseen 15 product approvals through the FDA and EMA and raised over $85 million in capital to fund breakthrough technologies. From 2017 to 2020, he consulted with multiple medical schools and biotech and pharmaceutical companies, and, from 2012 to 2017, he served as President, Chief Executive Officer and Director of Xeris Pharmaceuticals Inc. Mr. Baum holds a Master of Science in Technology Commercialization and a BBA in International Business and Marketing from the University of Texas.

Adam King is the CFO of QSAM Biosciences. He is also the Founder and CEO of King Consulting Group, where he provides a range of financial and reporting services for clients. Before founding King Consulting Group in January 2021, Mr. King was the CFO for Netsertive, a venture-backed digital marketing company. From 2016 to 2018, he was the Office Managing Audit Director for BDO’s Greenville, South Carolina, office, in addition to serving as Audit Director in Raleigh, North Carolina, and Boston, Massachusetts. While at BDO, Mr. King worked with various clients, from tech and life science start-ups to billion-dollar publicly traded companies. He holds a Bachelor of Science in Accounting from Elon University and is a CPA in Raleigh, North Carolina.

QSAM Biosciences Inc. (OTCQB: QSAM), closed Wednesday's trading session at $4.8125, up 6.9444%, on 100 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $3.50/$14.00.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

  • CNS Pharmaceuticals is a biopharmaceutical company that focuseson developing novel treatments for primary and metastaticcancers in the brain and central nervous system
  • The company is currently evaluating the efficacy of Berubicin,a novel anthracycline that appears to cross the blood-brainbarrier, in a potentially pivotal Phase 2 trial involvingpatients with recurrent glioblastoma multiforme (“GBM”)
  • CEO John Climaco recently participated in the Virtual Investor“Ask the CEO” Event in which he provided an update on recentkey events and plans for the future in addition to allaying theinvestors’ concerns regarding the recent reverse stock split
  • CNS Pharmaceuticals also announced the pricing of a publicoffering that closed December 5; the company intends to use thenet proceeds of the offering for its ongoing trial, R&D,and working capital

CNS Pharmaceuticals (NASDAQ: CNSP) CEO John Climaco recently participated in the Virtual Investor “Ask the CEO” Event held December 6. As part of the virtual event, Climacodiscussed his and the company’s background, provided an update onrecent key events and plans for the 2023 calendar year, andassuaged investors’ concerns regarding the recent reverse stocksplit. Lastly, Climaco also fielded questions from the investmentcommunity (https://ibn.fm/bEl2S).

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Wednesday's trading session at $2.1, off by 15.6627%, on 37,939 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.05/$41.40.

Recent News

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services (OTCQB: SHRG) is dedicated to maximizing shareholder value through theacquisition and development of innovative companies, products andtechnologies. The company recently introduced the traveling worldto a whole new approach to savings as well as a unique opportunityfor those looking for additional income in the gig economy throughthe inaugural event for Hapi Travel Destinations. “A wholly ownedsubsidiary of Sharing Services, Hapi Travel Destinations is aglobal leader in fun-filled, one-of-a-kind travel and offersexclusive travel-club membership… Sharing Services unveiled HapiTravel Destinations in September, noting that the uniquemembership-based travel club was specifically designed fortravelers to enjoy maximum savings and travel perks on the mostluxurious vacation getaways throughout the world while also savingmoney on ordinary daily personal or corporate travel,” a recentarticle reads. “Our timing could not be better,” Hapi Travel VPDave Dove is quoted as saying. “After two years of socialdistancing and limited travel, people are ready to get out andexperience new locations and revisit the places they love.Unfortunately, the rising costs of travel now make this difficultfor the average family. Our unique memberships are tailor-made togive access to deep savings for weekend getaways, resort vacations,business travel, flights and hotels. We back this program with a110% guarantee.”

To view the full article, visit https://ibn.fm/HudLe

Sharing Services Global Corporation (SHRG), formerly Sharing Services Inc., is a diversified company dedicated to maximizing shareholder value, operating through two primary subsidiaries: Elepreneurs Holdings, a direct-selling company, and Elevacity Holdings, a products company. Headquartered in Plano, Texas, SHRG markets and distributes Elevate-branded health and wellness products through an independent sales force of distributors called Elepreneurs.

Proprietary Products

SHRG’s current exclusive Elevate product offerings are marketed under the Elevacity brand, so named to signify the company’s commitment to elevating lives.

The Elevate health and wellness product line consists of nutraceutical products that SHRG refers to as D.O.S.E., which stands for dopamine, oxytocin, serotonin and endorphins – all of which are key hormones proven to promote happiness and well-being.

Elevacity brand products are carefully formulated, chosen and designed to support a single objective: elevate the happiness and well-being of the consumer.

Global Network of Elepreneurs

Elevacity products are shared and sold by a growing international network of home-based entrepreneurs, called Elepreneurs, operated by Elepreneurs Holdings. This SHRG subsidiary provides basic and advanced programs for both new and experienced entrepreneurs who are focusing on their direct-sales careers.

SHRG’s high-performing independent sales force follows the company’s Blue Ocean selling strategy, an approach that encourages individuals to seek new markets, lead, and to “stop competing and start creating.” The Blue Ocean strategy is based on the book, “Blue Ocean Strategy,” written by Professor Renée Mauborgne, who notes that “the lesson here is that the best defense is offense, and the best offense… is to make a blue ocean shift and create your own blue ocean.”

Following this selling strategy, SHRG’s Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

In addition, SHRG’s Elepreneurs use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary interactive video data collection and analysis technology and provides next-generation customer relationship management, lead generation, and video marketing software applications.

Continued Momentum as Industry Leader

These selling strategies have resulted in sharp and consistent revenue gains. In the company’s 10-Q filed with the SEC for the three months ended Oct. 31, 2019, SHRG reported sales of $38.8 million for fiscal Q2 2019, an increase of 116% over sales of $17.9 million reported for the comparable quarter of 2018. Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

SHRG’s consolidated operating earnings were $3.9 million in the fiscal quarter ended Oct. 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended Oct. 31, 2019, compared to 62.2% the prior year.

These numbers are continuing a trend established over the past two years. In fiscal Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018. Even earlier, the company reported sales of $85.9 million for fiscal year ended April 30, 2019. This represents a nine-fold increase, or $77.5 million jump, over the company’s revenues of $8.4 million the prior year.

These numbers bring SHRG’s sales revenues since December 2017 — when the company’s Elevate product line was released — to an impressive cumulative total of $169 million.

Preparing for Success

SHRG is well prepared to continue and accommodate for this growth. The company recently expanded its corporate footprint by moving to a 10,000-square-foot facility in Plano, Texas, that offers ample room to expand as the company grows and flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

In addition, the company has a seasoned, expert leadership team in place, led by John “JT” Thatch. Thatch was appointed president and CEO of SHRG in March 2018, bringing to the company his expertise obtained from successfully starting, owning and operating several businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist SHRG as the company aims to expand and increase revenues.

Contact
469.304.9400 x 201
Info@SHRGinc.com
http://www.SHRGinc.com

Sharing Services Global Corporation (SHRG), closed the day's trading session at $1.01, up 23.17%, on 276,351 volume with 217 trades. The average volume for the last 3 months is 279,074 and the stock's 52-week low/high is $0.27/$2.54.

Recent News

Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF)

The QualityStocks Daily Newsletter would like to spotlight Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF).

Precious metals such as silver and gold have traditionally seen a spike in demand during economic downturns. Their ability to maintain their valueduring periods of political and economic uncertainty makes themextremely attractive to investors who are looking to preserve thevalue of their assets and investments.

However, a surging dollar coupled with consecutive interest rate hikes by the U.S. Fed kept silver prices in check for a significant portion of the yearand eroded some of its appeal as a safe haven asset.

Even so, there are signs that silver may rally in 2023 and evenachieve the nearly decade-high levels it reached in early 2021. Spot silver prices have gone up by 20% over the past threemonths, and they may go up even higher over the course of 2023 dueto a variety of factors.

Record-low silver inventories at the London Bullion Market Association and New York Comexexchange, coupled with a tight silver physical market, have also pushed up demand and increased prices. All theseconditions suggest that extraction companies such as Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF) are likely to benefit from the upturn in the market as demandrises.

Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF) is a mineral exploration company engaged in advancing precious and base metal deposits in the state of Arizona. Its flagship copper-gold-zinc-silver asset is the Kay Mine Project, located in Yavapai County. The company also owns Sugarloaf Peak gold project in La Paz County.

The company in October 2022 received permit approval from the Bureau of Land Management (BLM) for two new drill pads, located approximately 1,200 meters west of the Kay Mine Deposit. These new pads will allow for testing of the company’s Western Target, while also allowing for drilling of additional coincident anomalies located between the Central and Western Targets. Construction of the drill road for the Central Target (located 500 meters west of the Kay Mine Deposit) is currently underway, with drilling expected to begin in November 2022. Road construction for the Western Target will begin upon confirmation of BLM acceptance of the company’s posted bond, with drilling expected to commence in Q1 2023.

The company is fully funded, with $60 million in cash as of June 30, 2022, to complete the remaining 18,000 meters planned for the Phase 2 program at Kay, as well as an additional 76,000 meters in the Phase 3 program (budgeted at $27 million), which will be used to test the numerous parallel targets heading west of the Kay Deposit, as well as the northern and southern extensions of the Kay Deposit.

Arizona Metals Corp. is based in Toronto, Canada.

Projects

Arizona Metals Corp. owns 100% of the Kay Mine property in Yavapai County, which is located on a combination of patented and BLM claims totaling 1,300 acres that are not subject to any royalties. An historic estimate by Exxon Minerals in 1982 reported a “proven and probable reserve of 6.4 million short tons at a grade of 2.2% copper, 2.8 grams per ton gold, 3.03% zinc, and 55 grams per ton silver.” The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported by Exxon, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a “qualified person” (as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects) before the historic estimate can be verified and upgraded to be a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource.

The company also owns 100% of the Sugarloaf Peak Property in La Paz County, which is located on 4,400 acres of BLM claims. Sugarloaf is a heap-leach, open-pit target and has a historic estimate of “100 million tons containing 1.5 million ounces (of) gold” at a grade of 0.5 grams per ton. The historic estimate at the Sugarloaf Peak Property was reported by Westworld Resources in 1983. The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a qualified person before the historic estimate can be verified and upgraded to a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource.

Market Opportunity

The World Gold Council, an industry association representing gold producers with hundreds of mining operations in nearly 50 countries around the world, reports that global demand for gold during the first six months of 2022 was 2,189 tons, a 12% increase in demand over the same period in 2021. Demand came primarily from gold bar and coin investors, jewelry consumers, central bank purchases to bolster currency reserves and technology manufacturing.

The average price per ounce for the period was $1,871, marking a 1% year-over-year increase. The council reported gold mine production for the period was up 3% over 2021 at 1,764 tons. For the remainder of 2022 and into 2023, the council projects flat gold demand with possible slight increases in gold mine production. The council notes that unpredictable geopolitical factors, the Ukraine war for example, and likelihood of global economic slowdown could have significant near-term impact on gold demand and prices.

Management Team

Marc Pais is President and CEO of Arizona Metals. He previously founded and served as President of Telegraph Gold (listed as Castle Mountain Mining), which was acquired by Equinox Gold, a TSX-listed mining company. He has seven years of experience as a Mining Analyst, with a focus on precious metals development companies. He holds a B.Sc. in Geological Engineering (Mineral Exploration) from Queen’s University in Canada.

David Smith is the Vice President, Exploration of Arizona Metals. He has 30 years of global precious metals exploration experience, including codiscovery of the Solidaridad/La Sabila deposit in Mexico with deposits estimated at 1 million ounces of gold. His core areas of expertise are managing mineral projects from acquisition to exploration, resource modeling and mineral project development. He holds an M.Sc. from the University of Oregon and an MBA from Pinchot University/Presidio Graduate School.

Paul Reid is the Executive Chairman of Arizona Metals. He previously founded and served as Executive Chairman of Telegraph Gold (listed as Castle Mountain Mining), which was acquired by Equinox Gold, a TSX-listed mining company. Paul has extensive experience as an Investment Banking professional, involved in raising capital, go-public transactions, and advisory services.

Vision Energy Corp. (OTCQX: AZMCF), closed Wednesday's trading session at $2.9, off by 2.3569%, on 81,167 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.30/$5.60.

Recent News

Cerberus Cyber Sentinel Corp. (NASDAQ: CISO)

The QualityStocks Daily Newsletter would like to spotlight Cerberus Cyber Sentinel Corp. (NASDAQ: CISO).

Cerberus Sentinel (NASDAQ: CISO), a Scottsdale, Arizona-based industry leader as a managedcybersecurity and compliance provider, today announced plans for acorporate rebrand and launch. Central to the rebranding is a changeof the company name to CISO Global, Inc. and an update to itscorporate logo. “CISO Global was founded to bring cybersecurityprofessionals together on a global basis,” said David Jemmett, CEOand founder of CISO Global. “We have assembled a world-classleadership team, and we have successfully brought together 16organizations globally. It is time for our name to reflect who weare as an organization.”

To view the full press release, visit https://ibn.fm/T5ElZ

To view the full press release, visit https://ibn.fm/fkDjc

Cerberus Cyber Sentinel Corp. (NASDAQ: CISO) is an industry leader in cybersecurity and compliance services. The company leverages an integrated approach to reduce noise and bridge common silos that often limit the effectiveness of cybersecurity programs. Pulling disparate technologies, teams, and vendors together, Cerberus helps its clients enjoy a simpler and more successful journey to cyber resilience. Since 2019, Cerberus Sentinel has worked to rapidly expand by acquiring world-class cybersecurity and compliance businesses with top-tier talent who utilize the latest technology to create innovative protection solutions.

The Cerberus Sentinel workforce is comprised of cybersecurity experts spanning not only global geographies, but also specialties, industries, regulatory frameworks and focus areas. Its team includes audit and compliance specialists, certified forensics experts, ethical hackers, IEEE® certified biometric professionals, security engineers, around-the-clock analysts, and more – all backed by the most respected credentials in the industry. On an ongoing basis, the company works to identify cyber talent that is culturally aligned and that offers operating leverage through both existing customer revenue and relationships.

Cerberus Sentinel has invested in enterprise solutions and executive talent to integrate its different organizations into an ecosystem that works together to provide complete cybersecurity through cross-pollination of solutions that begin at the network level and extend through technologies, people, policy, and practices. This ecosystem is intended to foster additional growth opportunities and drive overall recurring revenue. Once engaged, the company strives to become trusted advisors for customers’ cybersecurity and compliance demands by providing tailored security solutions based upon their organizational needs.

While cyber resilience requires cycles of continuous improvement, it is a journey that few in the current business and security climate seem to understand. With its deep bench of seasoned experts, Cerberus Sentinel works to simplify that journey for its growing customer base, straightening out the curves and speeding up the process to resilience along the way.

Cybersecurity is a Culture, Not a Product

Integrating compliance and security, including principles of security by design, Cerberus Sentinel helps its clients create an organization-wide culture of cybersecurity. Its offerings include audit and compliance, security operations center services, security engineering, virtual Chief Information Security Officer services, incident response, certified forensics, technical assessments and cybersecurity training.

In contrast to the majority of cybersecurity firms that specialize in a specific technology or service, Cerberus Sentinel seeks to differentiate itself by remaining technology agnostic, focusing on accumulating highly sought-after subject matter experts. Cerberus Sentinel believes that bringing together a world-class team of technological experts with multi-faceted proficiency in the critical aspects of cybersecurity is key to providing technology agnostic solutions to its clients in a business ecosystem that suffers from a chronic lack of highly skilled professionals.

Cerberus Sentinel’s goal is to create a culture of security and to help quantify, define and capture a return on investment from information technology and cybersecurity spending. Its end-to-end, holistic process covers every aspect of clients’ cybersecurity and compliance requirements in an effort to promote greater efficiency and strengthen awareness about the integral role of internal team members in the cybersecurity culture of an organization.

As a result of this strategy, Cerberus Sentinel customers receive an efficient engagement from a single partner that covers a wide range of their needs – addressing challenges more thoroughly and resolving problems more rapidly when compared to working with a host of vendors.

Market Outlook

According to an analysis by the firm Research and Markets, the global managed security services market was valued at $22.45 billion in 2020 and is projected to reach $77.01 billion by 2030, growing at a CAGR of 12.8% through the forecast period.

An expected increase in cybercrime, cost effectiveness of provided solutions and stringent mandatory government regulations aimed at protecting corporate data will drive the global managed security services market for the foreseeable future.

In addition, the documented and growing use of mobile devices in the workplace and the rise in captured and stored digital data serve to fuel market growth. Moreover, growing awareness about the critical nature of data security, the growing importance of e-business and demand for customized services is expected to offer ample opportunities for expansion of the market during the forecast period.

Management Team

David Jemmett is CEO and founder of Cerberus Sentinel. He has more than 35 years of executive management and technology experience with telecommunications, managed services, and cybersecurity consulting services. He previously held positions as CEO of GenResults, a leading provider of security consulting services and technology solutions, and as CTO and founder at ClearData Networks, a HIPAA-compliant HealthDATA cloud hosting platform.

Dave Bennett is COO at Cerberus Sentinel. Since 2015, he has served on the President’s STEM Advisory Board of Grand Canyon University. Before joining Cerberus Sentinel, he served as Chief Product Officer at Experian Health and as Senior Vice President, Product for Gainwell Technologies. He has also held positions as Vice President and Worldwide Head of Build, Healthcare and Life Sciences at DXC Technology, and as EVP, Product and Strategy at Orion Health.

Ashley Devoto is President and Chief Information Security Officer at Cerberus Sentinel. Over the past 17 years, Devoto has worked with the cybersecurity elite to design, build, and operate world-class cybersecurity programs for large, diverse organizations in both government and commercial enterprises. Prior to joining Cerberus, Devoto served as CISO for Booz Allen Hamilton, as business information security officer (BISO) at Bank of America, and as a cyberspace operations officer in the United States Air Force.

Deb Smith is CFO at Cerberus Sentinel. Prior to assuming that position, she was the company’s EVP, Finance and Accounting. She has also served as SVP, Global Accounting at International Cruise and Excursions Inc., and as Chief Accounting Officer for BeyondTrust, an information security software company. She has also held the positions of Corporate Controller at Aspect Software and Assistant Controller at JDA Software.

Cerberus Cyber Sentinel Corp. (NASDAQ: CISO), closed Wednesday's trading session at $2.74, off by 4.1958%, on 51,387 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.15/$49.00.

Recent News

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

The QualityStocks Daily Newsletter would like to spotlight BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV).

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturingand commercializing innovative immunotherapeutic products primarilyfor the treatment of infectious and autoimmune diseases. Aegis Capital Corp., which is dedicated to providing corporate finance, strategicadvisory and related services to public and private companiesacross multiple sectors and regions, acted as sole bookrunner on an$8 million underwritten public offering for BiondVaxPharmaceuticals. BiondVax expects to use the net proceeds from theoffering, together with its existing cash and cash equivalents, forthe advancement of its nanosized antibody (“NanoAb”) developmentprogram and general corporate purposes.

To view the full press release, visit https://ibn.fm/MNzAO

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. BiondVax anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

BiondVax has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, BiondVax will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. BiondVax anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future BiondVax drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is BiondVax’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Chief Engineer and Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at BiondVax. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at BiondVax. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining BiondVax, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at BiondVax. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to BiondVax through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), closed Wednesday's trading session at $3.2272, off by 0.395062%, on 17,534 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $3.0914/$34.90.

Recent News

India Globalization Capital Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital Inc. (NYSE American: IGC).

In early October, President Joseph Biden announced that he would pardon thousands of Americans who were convicted ofsimple marijuana possession at the federal level. President Bidenalso called on governors to begin the process of issuing pardonsfor similar cannabis convictions at the state level, saying in a public statement that no one should be jailed forjust possessing or using marijuana.

However, the pardon would not apply to noncitizens who did not have legal status when they were arrested andconvicted. At the time, the White House stated that the Office ofthe Pardon Attorney would soon make it possible for eligibleparties to apply for a certificate of pardon via a short application form.

On Tuesday, U.S. Pardon Attorney Elizabeth Oyer revealed that this short, 10-minute form is nearly ready and that theJustice Department would unveil it to the public. Oyer discussedthe practical and symbolic implications of Biden’s pardon during apanel discussion by Ohio State University’s Mortiz College of Law.The panel also involved Last Prisoner Project executive director and generalcounsel Sarah Gersten and University of Minnesota Law SchoolClemency project director JaneAnne Murray.

Meanwhile, aside from the debates on whether marijuana should orshouldn’t be legalized federally, several companies such as India Globalization Capital Inc. (NYSE American: IGC) are taking the pharmaceutical route of conducting preclinical andclinical development programs on cannabinoid-based medicines sothat FDA approval is secured and the therapies are availed throughthe hospital system.

India Globalization Capital Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule (www.clinicaltrials.gov). As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products (www.Holief.com) such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand (www.SundaySeltzer.com) that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.

IGC-AD1

IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.

TGR-63

The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

India Globalization Capital Inc. (NYSE American: IGC), closed Wednesday's trading session at $0.3499, off by 2.2626%, on 120,616 volume. The average volume for the last 3 months is 114,870 and the stock's 52-week low/high is $0.34/$1.19.

Recent News

SideChannel Inc. (OTCQB: SDCH)

The QualityStocks Daily Newsletter would like to spotlight SideChannel Inc. (OTCQB: SDCH).

SMBs are increasingly vulnerable to cyberattacks, from attacks oninternal customer and employee records to proprietary secrets, and,although there are no foolproof solutions, there are now affordableand proven ways for SMBs to significantly mitigate the risks

SideChannel’s team of vCISOs (virtual-based Chief InformationSecurity Officer) possess a combined 400-plus years of experiencein cybersecurity, offering creative solutions in the form of abespoke cybersecurity program perfectly sized for growingenterprises

The global cybersecurity market was valued at $139.77 billion in2021 and is expected to reach $155.83 billion in 2022

The rapid digitization of supply chains creates serious newsecurity risks. According to predictions by Gartner, 45% oforganizations worldwide will have experienced cyberattacks on theirsoftware supply chains by 2025. With 60% of the current workforceworking remotely, organizations are more vulnerable to attacks.They recommend that security leaders look beyond traditionalapproaches to security monitoring, detection, and response, tomanage wider risks (https://ibn.fm/JnH6G).SideChannel (OTCQB: SDCH) was featured in a recent article published by IT Brew,which delivers the latest news and analysis of trends shaping theIT industry, from cybersecurity and big data to softwaredevelopment. The piece discusses the post work-from-home (“WFH”)era and workers returning to the office with enhanced securitysetups. “In other words: The same security safeguards thatprotected users as they began working from home are still in effectin office environments. Software-defined networks (‘SD-WANs’), forexample, enforced access control at home, and they’ll likely find arole in the office, according to Brian Haugli, CEO at thecybersecurity and privacy firm SideChannel,” the article reads,further quoting Haugli on this trend. “Now, with the return to theoffice, people are seeing the value out of software-definednetworking, over having hardware-defined networking.”

To view the full press release, visit https://ibn.fm/XY5BS

SideChannel Inc. (OTCQB: SDCH) simplifies cybersecurity for mid-market companies by matching them with highly experienced information security officers at a cost lower than building an in-house information security team or hiring a full-time CISO.

SideChannel’s team of virtual Chief Information Security Officers (vCISOs) possesses a combined 400-plus years of experience in cybersecurity. They’ve honed their skills and abilities in places like Anthem, Dick’s Sporting Goods, Best Buy, TD Bank and the Pentagon. SideChannel lends this talent to clients, creating value in the form of a bespoke cybersecurity program perfectly sized for the growing enterprise.

SideChannel is committed to creating top-tier cybersecurity programs for SMBs to help them protect their data and assets. To date, SideChannel has created more than 50 multi-layered cybersecurity programs for its clients.

 

Reports show that cyberattacks on SMBs have increased in recent years, as organizations’ network attack surfaces have grown exponentially with remote and in-office workers increasingly relying on cloud environments, mobile devices, software applications and third-party suppliers to conduct business.

SideChannel continues expanding its service offerings, workforce and customer base, attracting over 20 virtual CISOs to serve across industries including fintech, biotech, healthcare, manufacturing, legal, defense and technology services. The company is based in Worcester, Massachusetts.

Market Opportunity

An analysis from ReportLinker states that the global cybersecurity market is expected to grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving cyber security market growth, according to the report.

A lack of cybersecurity professionals and the budget constraints among SMBs and start-ups in developing economies are expected to hinder market growth. Cybercriminals are using automated techniques to attack SMBs’ networks to take advantage of their weak security infrastructures. To save money, time and resources, SMBs are seeking cybersecurity solutions.

Enclave

Enclave expands upon SideChannel’s cybersecurity service offerings by solving a pervasive network security problem with a simple tool.

A comprehensive cloud and network security solution, Enclave enables IT teams to contain breaches faster, reduce network outages, minimize latency and strengthen overall security defense.

Enclave creates the foundation for a Zero Trust network security model IT can build upon.

With Enclave, IT can easily segment their company’s network, organize personnel and computing devices at the employee workload level, and implement security controls across all network segments.

Enclave was designed and purpose built to serve the growing security needs of SMBs, a traditionally underserved market that is more prone to cyberattacks but has limited protection due to smaller budgets, inadequate IT security staffing and a lack of cybersecurity awareness among top executives.

Enclave is an affordable and effective network security solution that shrinks the attack surface area exposed to a cyber intruder and significantly reduces the amount of effort required to operate securely.

Management Team

Brian Haugli is CEO of SideChannel. He has led programs for the U.S. Department of Defense, the Pentagon, and Fortune 500 companies. He is an expert on National Institute of Standards and Technology guidance, threat intelligence implementations and strategic organizational initiatives. He is a professor at Boston College, Woods College of Advancing Studies Master’s Program in Cybersecurity. He is also a contributing author for the Wiley book ‘Cybersecurity Risk Management’.

Ryan Polk is CFO at SideChannel. He has been the principal of Perissos Partners, an executive consulting firm, since June 2017. He also served in executive roles in the portfolio companies owned by Lacy Diversified, with combined revenue approaching $2 billion. He served as the Vice President for Corporate Financial Planning and Analysis for Brightpoint, a publicly traded, Fortune 500 mobile device logistics company. He earned a bachelor’s degree in accounting and industrial management from Purdue University.

Nicholas Hnatiw is Chief Technology Officer at SideChannel. Prior to joining the company, he served as the technical director for network operations supporting U.S. Cyber Command, U.S. Intelligence Agencies and other Department of Defense research organizations. He was also the CEO of Loki Labs, a cyber security firm. He earned a bachelor’s degree in computer engineering and computer science at the University of Massachusetts, Amherst.

Bill Roberts is SideChannel’s CISO. He most recently served as the vice president, IS & CISO for Hologic Inc., a global medical device company, where he established cyber security and IT compliance programs. Prior to Hologic, he was vice president of information security for Cytyc Corporation, which was acquired by Hologic in 2007. At Cytyc, he managed global IT as the company grew from 140 employees to 1,500 and from $40 million in revenue to over $750 million.

SideChannel Inc. (OTCQB: SDCH), closed Wednesday's trading session at $0.092, off by 16.3636%, on 125,322 volume. The average volume for the last 3 months is 125,322 and the stock's 52-week low/high is $0.06/$0.18.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

  • Luis Merchan was appointed President of Consumer Goods at Florain July 2020 before being appointed as the company’s CEO fivemonths later, and chairman of its Board of Directors in May2022
  • Merchan would lend his years of experience at Macy’s, where heled various sales and marketing initiatives, including the B2Bcorporate team responsible for bringing in $160 million inannual revenue
  • Under his leadership, Flora has transitioned from thedevelopment stage to a full-scale international distributorwith operations in over 12 countries worldwide. Mr. Merchan hasalso spearheaded several M&As, all of which have since setthe company up for rapid growth
  • Flora maintains its revenue guidance for FY 2022 to be between$35 and $45 million, incorporating revenue contributions fromits various operating divisions, including Vessel Brand

In July 2020, Flora Growth (NASDAQ: FLGC), a cannabis cultivator, brand manufacturer, and globaldistributor, appointed Luis Merchan as the President of ConsumerGoods. Mr. Merchan would lead the company’s CBD portfolio,eventually launching four unique brands in the United States andfacilitating the growth of the company’s operating divisions (https://cnw.fm/ZeVsJ). His performance would influence his appointment as CEO of thecompany five months later, taking over from Damian Lopez.

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.

Cultivation

Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Wednesday's trading session at $0.254, off by 2.3077%, on 454,142 volume. The average volume for the last 3 months is 454,142 and the stock's 52-week low/high is $0.23/$2.38.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.